Top Pharmaceutical Companies in Boston, MA (134)
Who We Are Chewy is where pet parents find everything they need for life with pets, from food to fun to pharmacy. We make pet care easier, more informed, and more joyful through fast, reliable delivery and award-winning 24/7 Customer Care, including access to pet health support when it’s needed. Founded in 2011, Chewy combines the convenience of online shopping with...
Chewy's Top Stability & Growth Strengths
Customer Loyalty & Retention: Autoship accounts for the vast majority of sales (over four-fifths) and is growing faster than total revenue, indicating a sticky, recurring base and higher retention. Evidence includes Autoship representing ~83% of FY2025 net sales and ~84.6% in Q2 FY2026 with high single‑digit to double‑digit growth.
Profitability: Operating metrics show expanding earnings power, with adjusted EBITDA up materially and margins improving alongside strong free cash flow. Observations include FY2025 adjusted EBITDA growth of ~26% with margin expansion and additional year‑over‑year gains reported in 1H FY2026.
Strong Market Position & Advantage: Chewy is characterized as the largest U.S. pet e‑tailer and a leading online pet‑supplies platform by GMV and digital presence, underpinning durable scale advantages. Multiple summaries highlight leadership in online pet retail, substantial Autoship penetration, and strong digital search share versus specialty peers.
Schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions and services for pharmaceutical, biotechnology, and materials science research. The predictive power of Schrödinger's software allows scientists to accelerate their research and development, reduce research costs, and make novel discoveries.
Schrödinger, Inc.'s Top Stability & Growth Strengths
Strong Revenue Growth: Recent results indicate total revenue increased year over year in 2025 and continued to rise in the latest reported quarter. Guidance and quarterly updates point to ongoing top-line expansion even as mix shifts occur.
Resilient & Sustainable Growth: Underlying annual contract value expanded and accelerated in 2026, with management indicating continued growth despite the transition to hosted licensing. This suggests the core subscription base is strengthening even when reported revenue timing varies.
Diversified Revenue Streams: Growth is visible in both the software business and the milestone-driven drug discovery segment. The latter stepped up meaningfully in recent periods, complementing steady software momentum.
Formation Bio is a tech-driven pharma company differentiated by radically more efficient drug development. Formation Bio has built a technology platform that optimizes all aspects of drug development, enabling more efficient trial design, faster trial completion, and higher quality trial data capture. Formation Bio acquires clinical-stage drugs from pharma and biotech and develops them faster and more efficiently, unlocking greater...
Formation Bio's Top Stability & Growth Strengths
Investor Backing & Capital Strength: Capital raising has accelerated, including a $372M Series D in 2024 with total funding reported in the hundreds of millions to expand the pipeline and AI platform. Valuation has stepped up from roughly $1.04B (2021) to about $1.48B post‑money (2024), signaling strengthened private‑market positioning.
Strategic Partnerships: Partnerships are expanding, highlighted by a collaboration with Sanofi and OpenAI to build AI software for drug development and increased business‑development capacity via Entrepreneurs in Residence. Engagements with large pharma partners, including Sanofi, underscore growing external validation and deal flow.
Product Line Growth: The pipeline is broadening through multiple in‑licenses—such as an anti‑CD226 program, a CNS‑penetrant TYK2 inhibitor, and a miR‑124 activator—and progression to first‑in‑human dosing of BLKR201 in 2026. Stated plans to reach 10–15 assets over 3–5 years align with recent portfolio expansion and clinical advancement.
Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from rare hematologic and musculoskeletal disorders with high unmet medical need
MENTOR Technical Group is a team of highly educated, superior trained, and dedicated professionals with expertise and experience to provide a complete portfolio of technical support and solutions for the FDA-regulated industry. MENTOR Technical Group delivers solutions with a flexible cost-effective approach to meet your company’s needs. Our purpose is to help you bridge the gap between your business strategies...
Agilathon, launched by the founders of Extension Engine, is a strategy and technology services firm focusing on decentralized, mobile clinical trial innovation. We have over 15 years of experience working with industry-leading partners to develop ePRO and eClinical technology solutions across 1000+ diverse clinical trials. Our experienced team collaborates with Contract Research Outsourcing (CRO) and pharmaceutical companies create solutions for...
SHYFT Analytics is an industry leader in cloud data management and mobile analytics for the global life sciences industry. SHYFT is used by pharmaceutical, biotech, medical device and other healthcare leaders from around the globe and across thousands of users. With over 10 years innovating in life sciences, SHYFT’s industry cloud platform is leading the transformation in healthcare and helping...
Verve Therapeutics is a clinical-stage biotechnology company created with a singular focus: to protect the world from heart disease. Founded by world-leading experts in cardiovascular medicine, human genetics and gene editing, the company aims to develop transformative, once-and-done therapies for coronary heart disease. Verve’s gene editing medicines are designed to safely edit the genome of adults and mimic naturally occurring...
Comanche is a biopharmaceutical company developing an investigational siRNA medicine for preterm preeclampsia, focusing on maternal and fetal medicine to lower risks for mothers and babies.
Elemental Machines is helping scientists improve experimental reproducibility and accelerate scientific discovery. With a new suite of connected products that harness the power of cloud-based software, machine learning and distributed sensors, Elemental Machines is giving scientists and researchers an easy, powerful and cost-effective solution fo
.jpg)
SDC delivers top-tier clinical trial services to pharmaceutical, biologic, and medical device/diagnostic companies since 2005. We are committed to providing experienced teams who will take ownership of your needs and are positively engaged in your projects. With strategic scientific consulting and clinical data services (biostatistics, data management/EDC, and IRT/IWRS) expertise at our core, our services are scalable via our diverse...
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on...
Kymera Therapeutics's Top Stability & Growth Strengths
Investor Backing & Capital Strength: The company reports $775M in cash as of March 31, 2025 and $1.6B as of December 31, 2025, extending its runway into 2029. An upsized equity raise and milestone receipts further support multi‑year development.
Strategic Partnerships: Kymera has significant collaborations with Sanofi, Gilead, GSK, and Vertex, including a $20M milestone from Sanofi tied to IRAK4 progress. These alliances provide funding, resources, and validation while accelerating key programs in immunology and oncology.
Innovation-Driven Growth: The pipeline features first‑in‑class oral immunology degraders such as KT‑621 (STAT6) with positive Phase 1b atopic dermatitis data and Fast Track, and KT‑579 (IRF5) entering Phase 1 in early 2026. A proprietary platform spanning heterobifunctional degraders and molecular glues enables steady pipeline advancement.
With an extensive network of terminals, gas stations, and retail stations, Global Partners helps people heat their homes, operate their businesses, and get where they’re going conveniently and quickly. Centered in the Northeast, the company is a third-generation, family-founded business with operations throughout the U.S.
Rapport Therapeutics aims to transform the treatment of neurological disorders through a precision medicine approach, precisely targeting disease-driving neurocircuits by leveraging receptor-associated proteins (RAPs). With this approach, Rapport can overcome the well-established limitations of today’s neuromedicines that act indiscriminately throughout the nervous system, resulting in suboptimal efficacy and burdensome side effects. Leading the hunt for precision medicines is a team...
Cerevel Therapeutics is a biopharmaceutical company focused on developing new therapies to treat disorders of the central nervous system (CNS). The company has a portfolio of experimental neuroscience therapies, which include three clinical-stage compounds and several pre-clinical compounds designed to target a broad range of CNS disorders, including Parkinson’s, Alzheimer’s, epilepsy, schizophrenia and addiction. Headquartered in the Greater Boston area,...
Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily of cell proteins and named for the visual resemblance of a scholar rock to protein structures, the clinical-stage company is focused on...
Galderma is the leading company solely dedicated to skin and advancing the future of dermatology. We deliver an innovative, science-based portfolio of sophisticated brands and services across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Through trusted partnerships with healthcare professionals, we ensure to meet individual consumer and patient needs with superior outcomes.
Mariana Oncology, a Novartis company, is a fully integrated next generation radiopharmaceutical company that brings together experts in ligand discovery, radiochemistry, radiobiology and oncology translational and clinical research in order to build a pipeline across a range of solid tumor types. Our mission at Mariana is to discover and develop safe, effective, and highly targeted radiopharmaceuticals.
YonaLink provides EHR-to-EDC streaming and AI-driven CRF mapping to assist with clinical trial data management and improve trial efficiency and data quality.
KCR is a clinical development solutions provider creating value for emerging biotechnology organizations. Founded in 1997, our expert teams support clients with full-service clinical development capabilities. As part of the ICON organization, KCR serves clients globally with key operations hubs in Boston, US, Berlin, Germany, and Warsaw, Poland. KCR’s bespoke approach to service delivery for emerging Biotech companies combined with the...
